Informal caregiving burden in advanced non-small cell lung cancer: The HABIT study. Journal of Thoracic Oncology 2 (6), 475–480. Erratum in: (2007). Journal of Thoracic Oncology 2 (7), 676.Gridelli C, et al. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT...
et al. First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial. Nat Med 29, 2079–2086 (2023). https://doi.org/10.1038/s41591-023-02461-x Download citation Received11 December 2022 Accepted14 June 2023 Published24 July 2023 Issue Date...
Non-small-cell lung cancer (NSCLC) is a major global health problem and is the leading cause of cancer death worldwide. Current treatment involves nonspecific, nonselective cytotoxic chemotherapy, which results in only a modest increase in survival and causes significant toxicity to the patient. Ta...
This study's aim was to assess economic data regarding the home assistance burden for advanced non-small cell lung cancer (NSCLC) patients in Italy. One hundred four NSCLC patients in second-line chemotherapy (2LC) or in supportive therapy (ST) were enrolled in 18 Italian oncology departments...
Journal of Biomedical Science (2020) 27:82 https://doi.org/10.1186/s12929-020-00676-5 REVIEW Open Access Precision radiotherapy for non-small cell lung cancer Wen-Chi Yang1,2, Feng-Ming Hsu1,2*† and Pan-Chyr Yang2,3*† Abstract Precision medicine is becoming the standard of care ...
Small Cell Lung Cancer JAMA Oncology Research Letter May 1, 2018 This cohort study examines the association of concomitant genetics alterations with response to treatment with epidermal growth factor receptor tyrosine kinase inhibitors among patients with EGFR-mutant advanced non–small cell lung cancer....
Most non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitor (TKI) therapy. However, about 30% exhibit primary resistance to EGFR TKI therapy. Here we report that Met protein expression and phosphorylation...
Non-small cell lung cancer NTA: Nanoparticle tracking analysis OS: Overall survival PD: Progressive disease PD-L1: Programmed cell death protein ligand-1 PET: Positron emission tomography PFS: Progression-free survival PR: Partial response RECIST: Response evaluation criteria in solid tumor...
In our knowledge, no study has explored TLR3 protein expression in non-small-cell lung cancer (NSCLC). With the idea that the TLR3 expression could represent a new prognostic marker for NSCLC, we focus our attention on expression of TLR3 in patients with stage I NSCLC because for these pa...
The response rate to immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 20%. To improve this figure, several early phase clinical trials combining novel immunotherapeutics with immune checkpoint blockade have been initiate